What is Alimera Sciences, Inc. (ALIM) stock price today?

Alimera Sciences, Inc. (ALIM) is currently trading at $5.54, down 0.18% today.

What is ALIM P/E ratio?

Alimera Sciences, Inc.'s P/E ratio is -7.01. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is ALIM return on equity (ROE)?

Alimera Sciences, Inc.'s return on equity (ROE) is -159.01%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Alimera Sciences, Inc.'s market cap?

Alimera Sciences, Inc. has a market capitalization of $301.29M.

NASDAQ · Drug Manufacturers - Specialty & Generic

Alimera Sciences, Inc. (ALIM) Stock

$5.54 -0.18% NASDAQ: ALIM Healthcare

Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States.

Valuation

Metric	Value
Price	$5.54
Market Cap	$301.29M
P/E Ratio	-7.01
P/B Ratio	3.07
P/S Ratio	3.73
EPS (TTM)	$-0.79
52-Week High	$5.65
52-Week Low	$2.61
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-159.01%
ROA	-13.11%
ROCE	-1.47%
Gross Margin	75.75%
Operating Margin	-2.39%
Net Margin	-24.93%
Debt/Equity	1.46
Current Ratio	2.39

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$54.0M	$51.0M	$59.0M	$54.0M	$81.0M
Operating Profit	$-5.0M	$-1.0M	$0	$-12.0M	$-2.0M
Net Profit	$-10.0M	$-5.0M	$-4.0M	$-18.0M	$-20.0M
EPS	$-2.19	$-1.04	$-0.66	$-2.59	$-0.79
Op Margin	-9.8%	-1.0%	-0.3%	-21.5%	-2.4%

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$50.0M	$51.0M	$59.0M	$43.0M	$154.0M
Total Liabilities	$55.0M	$59.0M	$61.0M	$63.0M	$107.0M
Cash	$9.0M	$11.0M	$17.0M	$5.0M	$12.0M
Borrowings	$39.0M	$45.0M	$44.0M	$44.0M	$67.0M

Latest News

Oil ticks up after selloff as talks to end US-Iran war remain uncertain Reuters · Aug 4, 2026 HSS Extends Its National Leadership with 17th Consecutive No. 1 Ranking in Orthopedics and No. 3 Ranking in Rheumatology by U.S. News & World Report Business Wire · Aug 4, 2026 CRK Q2 Deep Dive: Haynesville Well Optimization and Midstream Monetization Shape Outlook StockStory · Aug 4, 2026 The Urban Planning and Natural Resources Bureau of Shenzhen Municipality Hosts Global Urban Governance Forum, Marks Global Debut of Urban Index of Shenzhen (UIS) Products TMX Newsfile · Aug 4, 2026 Verisante Technology, Inc. Announces Resignation of Director TMX Newsfile · Aug 4, 2026

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$-4.0M	$-2.0M	$-3.0M	$-10.0M	$-14.0M
Investing Cash Flow	$0	$-1.0M	$-1.0M	$-1.0M	$-226.0M
Financing Cash Flow	$0	$0	$0	$0	$-4.0M
Net Cash Flow	$-4.0M	$2.0M	$5.0M	$-11.0M	$7.0M
Free Cash Flow	$-4.0M	$-3.0M	$-4.0M	$-10.0M	$-90.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.03
EV / EBITDA	-319.82
FCF Yield	-29.80%
Quick Ratio	2.31
Interest Coverage	-0.19
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ADMPAdamis Pharmaceuticals Corporation	$0.78	+0.85%	-0.06	$7.25M	0.00%
ATNXAthenex, Inc.	$0.20	+0.00%	-0.01	$2.33M	0.00%
CPHIChina Pharma Holdings, Inc.	$0.75	-13.53%	-0.65	$30.45M	0.00%
CYTHCyclo Therapeutics, Inc.	$0.72	+0.00%	-0.59	$23.59M	0.00%
DERMJourney Medical Corporation	$5.68	-3.89%	-29.64	$156.32M	0.00%

About Alimera Sciences, Inc.

Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.

Alimera Sciences, Inc. is headquartered in US.

Alimera Sciences, Inc. (ALIM) stock trades at $5.54 with a market capitalization of $301.29M. The stock is valued at a negative price-to-earnings (P/E) ratio of -7.01, reflecting a net loss over the last twelve months, price-to-book of 3.07, price-to-sales of 3.73. Over the past 52 weeks the stock has ranged between $2.61 and $5.65, and currently trades 1.9% below its 52-week high.

On profitability, Alimera Sciences, Inc. generates a return on equity (ROE) of -159.01% (negative, reflecting a net loss), return on capital employed of -1.47%, an operating margin of -2.39%, a net profit margin of -24.93%.

Official website: alimerasciences.eu